Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01794793 · ClinicalTrials.gov registry record · Phase 4
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
A Phase 4 study, sponsored by Recordati Group.
- Completed
- Registry status
- Phase 4
- Development phase
- 337
- Enrollment target
NCT01794793: Completed Phase 4 study, sponsored by Recordati Group.
NCT01794793 is a Phase 4 study that has completed, run by Recordati Group. The registered enrollment target is 337 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01794793, a Phase 4 study, has completed, sponsored by Recordati Group.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 337 participants
- Enrollment target
Study Summary
The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
Primary Outcome
Collect long term safety data, i.e. SAEs and AEs. SAES will be reviewed and reported as part of the regular pharmacovigilance activities.
Interventions
- DRUG Cabergoline
- DRUG Pasireotide
- DRUG Pasireotide LAR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 337 participants |
| Start Date | 2013-06-10 |
| Est. Completion | 2023-07-25 |
| Phase | Phase 4 |
What the finished NCT01794793 record still lists
NCT01794793 is an interventional study that assigns participants to a tested intervention. The registered 337 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 3 interventions - of which Cabergoline is the first listed.
NCT01794793 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01794793 about?
NCT01794793 is a clinical study titled "Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies". The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
What is the current status of trial NCT01794793?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 337 participants. The study started on 2013-06-10. Estimated completion is 2023-07-25.
What interventions are being tested in trial NCT01794793?
The interventions under investigation include: Cabergoline (DRUG), Pasireotide (DRUG), Pasireotide LAR (DRUG).
Who is sponsoring clinical trial NCT01794793?
This trial is sponsored by Recordati Group, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01794793's enrollment target sits among peer trials
337 250th of 2000 higher than 1,751 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03253263 · 338 participants · Phase 2
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
- NCT05658731 · 338 participants · NA
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
- NCT06022939 · 338 participants · Phase 3
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- NCT03947385 · 336 participants · Phase 1
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI